These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 12607287

  • 1. [Serotonin 2A receptor gene polymorphism and clinical efficacy of fluvoxamine in children with autistic disorder].
    Sugie Y, Sugie H, Fukuda T, Ito M, Ohzeki T.
    No To Hattatsu; 2003 Jan; 35(1):23-8. PubMed ID: 12607287
    [Abstract] [Full Text] [Related]

  • 2. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism.
    Sugie Y, Sugie H, Fukuda T, Ito M, Sasada Y, Nakabayashi M, Fukashiro K, Ohzeki T.
    J Autism Dev Disord; 2005 Jun; 35(3):377-85. PubMed ID: 16119478
    [Abstract] [Full Text] [Related]

  • 3. [Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder].
    Fukuda T, Sugie H, Ito M, Sugie Y.
    No To Hattatsu; 2001 Jul; 33(4):314-8. PubMed ID: 11494573
    [Abstract] [Full Text] [Related]

  • 4. [Studies on the adverse effects of fluvoxamine treatment in children with autistic disorder: correlation with genetic polymorphism in serotonin related genes].
    Sugie Y, Sugie H, Fukuda T, Ito M, Ohzeki T.
    No To Hattatsu; 2003 May; 35(3):233-7. PubMed ID: 12755054
    [Abstract] [Full Text] [Related]

  • 5. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
    Sato K, Yoshida K, Takahashi H, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K.
    Neuropsychobiology; 2002 May; 46(3):136-40. PubMed ID: 12422060
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
    McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH.
    Arch Gen Psychiatry; 1996 Nov; 53(11):1001-8. PubMed ID: 8911223
    [Abstract] [Full Text] [Related]

  • 7. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [Abstract] [Full Text] [Related]

  • 8. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder.
    Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM.
    J Clin Psychopharmacol; 2004 Feb; 24(1):49-55. PubMed ID: 14709947
    [Abstract] [Full Text] [Related]

  • 9. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK, Kozak MJ, Liebowitz M, White KL.
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [Abstract] [Full Text] [Related]

  • 10. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H, Jia F, Han H, Wang S, Guo G, Quan D, Li G, Huang H.
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine.
    Shimodozono M, Kawahira K, Kamishita T, Ogata A, Tohgo S, Tanaka N.
    Int J Neurosci; 2002 Oct; 112(10):1173-81. PubMed ID: 12587520
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M.
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [Abstract] [Full Text] [Related]

  • 15. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder.
    Rinne T, van den Brink W, Wouters L, van Dyck R.
    Am J Psychiatry; 2002 Dec; 159(12):2048-54. PubMed ID: 12450955
    [Abstract] [Full Text] [Related]

  • 16. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
    Fabre L, Birkhimer LJ, Zaborny BA, Wong LF, Kapik BM.
    Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
    [Abstract] [Full Text] [Related]

  • 17. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study.
    Ottevanger EA.
    Encephale; 1995 Jun; 21(4):317-21. PubMed ID: 7588171
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
    Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT.
    J Am Acad Child Adolesc Psychiatry; 2001 Feb; 40(2):222-9. PubMed ID: 11211371
    [Abstract] [Full Text] [Related]

  • 20. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling.
    Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C.
    Biol Psychiatry; 2000 May 01; 47(9):813-7. PubMed ID: 10812040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.